COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00413218




Registration number
NCT00413218
Ethics application status
Date submitted
18/12/2006
Date registered
19/12/2006
Date last updated
15/02/2019

Titles & IDs
Public title
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
Scientific title
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
Secondary ID [1] 0 0
WSA-CS-008
Secondary ID [2] 0 0
9766-CL-0105
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Candidiasis, Invasive 0 0
Candidemia 0 0
Mycoses 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents
Blood 0 0 0 0
Other blood disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Isavuconazole
Treatment: Drugs - Caspofungin
Treatment: Drugs - Voriconazole

Experimental: Isavuconazole (ISA) - Participants received 3 intravenous (IV) loading doses of 200 mg of isavuconazole on days 1 and 2, followed by an IV maintenance dose of 200 mg once daily from day 3 to day 56. On day 11 at the discretion of the investigator, non-neutropenic patients could switch from IV to oral therapy. Oral therapy consisted of 200 mg isavuconazole twice daily.

Active Comparator: Caspofungin (CAS)/Voriconazole - Participants received 1 intravenous (IV) loading dose of 70 mg CAS on day 1, followed by an IV maintenance dose of 50 mg CAS from day 2 to day 56. On day 11 at the discretion of the investigator, non-neutropenic patients could switch from IV CAS to oral voriconazole comprising of a loading dose of 400 mg twice daily (BID) on the first day of oral therapy followed by standard dosing of 200 mg BID thereafter.


Treatment: Drugs: Isavuconazole
Administered by intravenous infusion.

Treatment: Drugs: Caspofungin
Administered by intravenous infusion.

Treatment: Drugs: Voriconazole
Administered by intravenous infusion.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Overall Response of Success at the End of Intravenous Therapy (EOIV) as Determined by the Data Review Committee (DRC) Based on the Assessments of Clinical and Mycological Responses as Well as Alternative Systemic AFT Use - A Data Review Committee (DRC) was established from independent experts in the field of fungal infections to determine diagnosis and outcomes independently of the investigators and sponsor. Success was defined as clinical response (complete or partial) and mycological response (eradication or presumed eradication) without the use of alternative systemic antifungal therapy (AFT) within 48 hours after the last dose of IV study medication.
Timepoint [1] 0 0
End of Intravenous Treatment (EOIV) (Days 11-56)
Secondary outcome [1] 0 0
Percentage of Participants With Overall Response of Success at Follow Up Visit 1 (FU1-2 Weeks After End of Treatment (EOT)) as Determined by the DRC Based on the Assessments of Clinical, Mycological Responses and Antifungal Therapy (AFT) - A data review committee (DRC) was established from independent experts in the field of fungal infections to determine diagnosis and outcomes independently of the investigators and sponsor. Success was defined as clinical response (complete or partial) and mycological response (eradication or presumed eradication), without the use of alternative systemic AFT within 48 hours after the last dose of IV study medication.
Timepoint [1] 0 0
End of Treatment (EOT) (Day 56) and FU1 (2 weeks after end of treatment)
Secondary outcome [2] 0 0
Percentage of Participants With Overall Response of Success at EOT and Follow Up Visit 2 (FU2) as Determined by the DRC Based on the Assessments of Clinical and Mycological Responses as Well as Alternative Systemic AFT Use at EOT and FU2 - A data review committee (DRC) was established from independent experts in the field of fungal infections to determine diagnosis and outcomes independently of the investigators and sponsor. Success was defined as clinical response (complete or partial) and mycological response (eradication or presumed eradication), without the use of alternative systemic antifungal therapy AFT within 48 hours after the last dose of IV study medication (for EOT analysis) or for continued treatment of the primary infection, or for recurrent or emergent infection by FU2, with no recurrent or emergent infection by FU2 (for FU2 analysis).
Timepoint [2] 0 0
EOT (Day 56) and FU2 (6 weeks after end of treatment)
Secondary outcome [3] 0 0
Percentage of Participants With Clinical Response of Success at EOIV, EOT, FU1 and FU2 as Determined by the Data Review Committee (DRC) - A data review committee (DRC) was established from independent experts in the field of fungal infections to determine diagnosis and outcomes independently of the investigators and sponsor. Success was defined as clinical response (complete or partial).
Timepoint [3] 0 0
EOIV (Days 11-56), EOT (Day 56), FU1 (2 weeks after end of treatment) and FU2 (6 weeks after end of treatment)
Secondary outcome [4] 0 0
Percentage of Participants With Mycological Response of Success at EOIV, EOT, FU1 and FU2 as Determined by the Data Review Committee (DRC) - A data review committee (DRC) was established from independent experts in the field of fungal infections to determine diagnosis and outcomes independently of the investigators and sponsor. Success was defined as mycological response (Eradication or Presumed Eradication).
Timepoint [4] 0 0
EOIV (Days 11-56), EOT (Day 56), FU1 (2 weeks after end of treatment) and FU2 (6 weeks after end of treatment)
Secondary outcome [5] 0 0
Percentage of Participants With Mycological Response of Success at Day 7 and EOT as Determined by The Investigator - Success was defined as mycological response (eradication or presumed eradication).
Timepoint [5] 0 0
Day 7 and EOT (Day 56)
Secondary outcome [6] 0 0
Percentage of Participants With Clinical Response of Success at Day 7 and EOT as Determined by The Investigator - Investigators defined clinical response as success if participants exhibited complete or partial clinical response after evaluation of clinical signs and symptoms.
Timepoint [6] 0 0
Day 7 and EOT (Day 56)
Secondary outcome [7] 0 0
All-Cause Mortality (ACM) at Day 14 and Day 56 - All-cause mortality is represented as the percentage of participants who died on or before the analysis day. Participants who were lost to follow-up (i.e., unknown survival status) before the analysis day were counted as death. All-cause mortality was examined on Day 14 and Day 56.
Timepoint [7] 0 0
Day 14 and Day 56
Secondary outcome [8] 0 0
Time to First Confirmed Negative Culture - The first confirmed negative blood culture was defined as the first negative blood culture on or after first dose followed by a second negative blood culture at least 24 hours apart without any positive blood cultures in between. A participant without a confirmed negative blood culture was censored on the participant's last visit day. This endpoint was analyzed for mITT participants with candidemia only using the Kaplan-Meier method. Only participants with at least one positive blood culture on or prior to first dose and the culture not resolved prior to first dose were included in this analysis
Timepoint [8] 0 0
Day 1 up to FU1 (2 weeks after EOT (Day 56))

Eligibility
Key inclusion criteria
- Patients with candidemia or with an invasive Candida infection

- Presence of fever, hypothermia or other appropriate local sign of infection

- Female patients must be non-lactating and at no risk of pregnancy
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients with a sole diagnosis of mucocutaneous candidiasis, i.e. oropharyngeal,
esophageal or genital candidiasis; or candidal lower urinary tract infection or
Candida isolated solely from respiratory tract specimens

- Patients with candidemia who failed a previous antifungal therapy for the same
infection

- Patients previously enrolled in a phase III study with isavuconazole

- Patients with a body weight <40kg

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Fremantle Hospital - Fremantle
Recruitment hospital [2] 0 0
Mater Adult Hospital - South Brisbane
Recruitment hospital [3] 0 0
Westmead Hospital - Westmead
Recruitment hospital [4] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 0 0
6160 - Fremantle
Recruitment postcode(s) [2] 0 0
- South Brisbane
Recruitment postcode(s) [3] 0 0
- Westmead
Recruitment postcode(s) [4] 0 0
4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Idaho
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Indiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Louisiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Montana
Country [11] 0 0
United States of America
State/province [11] 0 0
New Jersey
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
Argentina
State/province [16] 0 0
Capital Federal
Country [17] 0 0
Argentina
State/province [17] 0 0
Ciudad Autonoma
Country [18] 0 0
Argentina
State/province [18] 0 0
La Boca
Country [19] 0 0
Belgium
State/province [19] 0 0
Brussels
Country [20] 0 0
Belgium
State/province [20] 0 0
Bruxelles
Country [21] 0 0
Belgium
State/province [21] 0 0
Gent
Country [22] 0 0
Belgium
State/province [22] 0 0
Leuven
Country [23] 0 0
Brazil
State/province [23] 0 0
Belo Horizonte
Country [24] 0 0
Brazil
State/province [24] 0 0
Curitiba
Country [25] 0 0
Brazil
State/province [25] 0 0
Porto Alegre
Country [26] 0 0
Brazil
State/province [26] 0 0
Rio de Janeiro
Country [27] 0 0
Brazil
State/province [27] 0 0
Santa Maria
Country [28] 0 0
Brazil
State/province [28] 0 0
São Paulo
Country [29] 0 0
Canada
State/province [29] 0 0
Alberta
Country [30] 0 0
Canada
State/province [30] 0 0
Ontario
Country [31] 0 0
Canada
State/province [31] 0 0
Quebec
Country [32] 0 0
Chile
State/province [32] 0 0
Puente Alto Santiago
Country [33] 0 0
Chile
State/province [33] 0 0
Santiago
Country [34] 0 0
Chile
State/province [34] 0 0
Temuco
Country [35] 0 0
China
State/province [35] 0 0
Chengdu
Country [36] 0 0
China
State/province [36] 0 0
Shanghai
Country [37] 0 0
France
State/province [37] 0 0
Strasbourg
Country [38] 0 0
France
State/province [38] 0 0
Vandoeuvre les Nancy
Country [39] 0 0
Germany
State/province [39] 0 0
Berlin
Country [40] 0 0
Germany
State/province [40] 0 0
Freiburg
Country [41] 0 0
Germany
State/province [41] 0 0
Koeln
Country [42] 0 0
Germany
State/province [42] 0 0
Leipzig
Country [43] 0 0
Germany
State/province [43] 0 0
Luebeck
Country [44] 0 0
Germany
State/province [44] 0 0
Wuerzburg
Country [45] 0 0
Hungary
State/province [45] 0 0
Debrecen
Country [46] 0 0
Hungary
State/province [46] 0 0
Györ
Country [47] 0 0
India
State/province [47] 0 0
Delhi
Country [48] 0 0
India
State/province [48] 0 0
Karna
Country [49] 0 0
India
State/province [49] 0 0
Kerala
Country [50] 0 0
India
State/province [50] 0 0
Mahara
Country [51] 0 0
India
State/province [51] 0 0
Chennai
Country [52] 0 0
India
State/province [52] 0 0
Hyderabad
Country [53] 0 0
India
State/province [53] 0 0
Kolkata
Country [54] 0 0
India
State/province [54] 0 0
Vellore Tamilnadu
Country [55] 0 0
Israel
State/province [55] 0 0
Afula
Country [56] 0 0
Israel
State/province [56] 0 0
Haifa
Country [57] 0 0
Israel
State/province [57] 0 0
Holon
Country [58] 0 0
Israel
State/province [58] 0 0
Jerusalem
Country [59] 0 0
Israel
State/province [59] 0 0
Kfar-Saba
Country [60] 0 0
Israel
State/province [60] 0 0
Petah
Country [61] 0 0
Israel
State/province [61] 0 0
Ramat Gan
Country [62] 0 0
Israel
State/province [62] 0 0
Tel Aviv
Country [63] 0 0
Italy
State/province [63] 0 0
Bologna
Country [64] 0 0
Italy
State/province [64] 0 0
Brescia
Country [65] 0 0
Italy
State/province [65] 0 0
Genova
Country [66] 0 0
Italy
State/province [66] 0 0
Verona
Country [67] 0 0
Lebanon
State/province [67] 0 0
Beirut
Country [68] 0 0
Malaysia
State/province [68] 0 0
Ampang
Country [69] 0 0
Malaysia
State/province [69] 0 0
Kuala Lumpur
Country [70] 0 0
Mexico
State/province [70] 0 0
Guadalajara
Country [71] 0 0
Mexico
State/province [71] 0 0
Mexico
Country [72] 0 0
Mexico
State/province [72] 0 0
Monterrey
Country [73] 0 0
New Zealand
State/province [73] 0 0
Auckland
Country [74] 0 0
New Zealand
State/province [74] 0 0
Hamilton
Country [75] 0 0
Philippines
State/province [75] 0 0
Cavite City
Country [76] 0 0
Philippines
State/province [76] 0 0
Manila
Country [77] 0 0
Russian Federation
State/province [77] 0 0
Moscow
Country [78] 0 0
Singapore
State/province [78] 0 0
Singapore
Country [79] 0 0
South Africa
State/province [79] 0 0
Lyttelton Centurion
Country [80] 0 0
Spain
State/province [80] 0 0
Barcelona
Country [81] 0 0
Switzerland
State/province [81] 0 0
Geneva
Country [82] 0 0
Switzerland
State/province [82] 0 0
Zurich
Country [83] 0 0
Thailand
State/province [83] 0 0
Bangkoknoi
Country [84] 0 0
Thailand
State/province [84] 0 0
Hat Yai
Country [85] 0 0
Thailand
State/province [85] 0 0
Muang
Country [86] 0 0
Thailand
State/province [86] 0 0
Ratchathewi

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Astellas Pharma Inc
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Basilea Pharmaceutica
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study is to compare the safety and efficacy of isavuconazole versus
caspofungin followed by voriconazole in the treatment of candidemia and other invasive
Candida infections.
Trial website
https://clinicaltrials.gov/show/NCT00413218
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Astellas Pharma Global Development
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications